Higher LDH levels linked to increased heart failure events in HFrEF patients

This analysis used data from the Phase 3, randomized controlled GALACTIC-HF trial, which evaluated omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF). The study population included 8,179 patients with HFrEF. The investigation focused on baseline lactate dehydrogenase (LDH) levels as an exposure variable, analyzing their association with clinical outcomes. The comparator was the lowest LDH quartile (Q1: 155 U/L). The primary outcome was a composite of first heart failure event or cardiovascular death.

The primary analysis showed that higher LDH levels were independently associated with a higher risk of the primary outcome. The hazard ratios (HR) and 95% confidence intervals (CI) for each quartile compared to Q1 were: Q2 (183 U/L; 25th-75th percentile: 177-188 U/L) HR: 1.15, 95% CI: 1.02-1.31; Q3 (207 U/L; 25th-75th percentile: 201-215 U/L) HR: 1.39, 95% CI: 1.23-1.58; Q4 (253 U/L; 25th-75th percentile: 236-280 U/L) HR: 1.84, 95% CI: 1.62-2.08. The direction of association was positive, meaning higher LDH levels corresponded to higher risk.

No key secondary outcomes were reported for this analysis. The study did not report specific data on secondary clinical endpoints beyond the primary composite outcome.

Safety and tolerability findings were not reported for this analysis of LDH levels. The original GALACTIC-HF trial reported on the safety of omecamtiv mecarbil, but this specific analysis did not include adverse event rates, serious adverse events, or discontinuation rates related to LDH measurement.

These results add to the understanding of biomarkers in HFrEF. Prior landmark studies have established various prognostic models, such as the PREDICT-HF risk model. This analysis found that adding baseline LDH improved model discrimination for the primary outcome, as measured by Harrell's C statistic, integrated discrimination improvement (IDI), and net reclassification index (NRI).

Key methodological limitations are not detailed in the provided input. The analysis is observational within an RCT, so it can only report associations, not causality. The study explicitly notes that LDH is a nonspecific measure of cellular injury. The follow-up duration for this analysis was not reported.

For clinical practice, these findings suggest that baseline LDH levels may provide incremental prognostic information for patients with HFrEF when added to existing risk models. However, LDH should not be used as a standalone test to guide therapy decisions, as the association is not causal.

Unanswered questions remain. It is not known if monitoring LDH levels over time would change management or outcomes. The specific mechanisms linking higher LDH to worse outcomes in HFrEF were not explored. The generalizability of these findings to other HFrEF populations or settings requires further study.